https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48759 10 pack years and/or distant metastases). Patients were randomized (1:1) to receive radiation therapy (70 Gy in 35 fractions) with either weekly cisplatin, 7 doses of 40 mg/m2, or cetuximab, loading dose of 400 mg/m2 followed by 7 weekly doses of 250 mg/m2. The primary outcome was symptom severity assessed by the MD Anderson Symptom Inventory Head and Neck Symptom Severity Scale from baseline to 13 weeks postcompletion of radiation therapy using the area under the curve. Trial was registered on ClinicalTrials.gov: NCT01855451. Results: Between June 17, 2013, and June 7, 2018, 189 patients were enrolled, with 92 in cisplatin arm and 90 in cetuximab included in the main analysis. There was no difference in the primary endpoint of symptom severity; difference in area under the curve cetuximab-cisplatin was 0.05 (95% confidence interval [CI], –0.19, 0.30), P = .66. The T-score (mean number of ≥grade 3 acute adverse events) was 4.35 (standard deviation 2.48) in the cisplatin arm and 3.82 (standard deviation 1.8) in the cetuximab arm, P = .108. The 3-year failure-free survival rates were 93% (95% CI, 86%-97%) in the cisplatin arm and 80% (95% CI, 70%-87%) in the cetuximab arm (hazard ratio = 3.0 [95% CI, 1.2-7.7]); P = .015. Conclusions: For patients with low-risk HPV-associated oropharyngeal cancer, radiation therapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared with radiation therapy and weekly cisplatin. Radiation therapy and cisplatin remain the standard of care.]]> Wed 05 Apr 2023 13:48:31 AEST ]]> From inside the bubble: migrants' perceptions of communication with the cancer team https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12251 Sat 24 Mar 2018 08:08:09 AEDT ]]> Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29325 Sat 24 Mar 2018 07:34:20 AEDT ]]> The next generation of the supportive care needs survey: a brief screening tool for administration in the clinical oncology setting https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22301 Sat 24 Mar 2018 07:11:06 AEDT ]]> A bridge between cultures: interpreters' perspectives of consultations with migrant oncology patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23157 Sat 24 Mar 2018 07:10:35 AEDT ]]>